Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 37kWORD 9k
16 January 2020
E-000256/2020
Question for written answer
to the Commission
Rule 138
Maria Grapini
 Answer in writing 
 Subject: Combating antimicrobial resistance

According to a new report by the European Court of Auditors, the EU has so far made little progress in combating ‘superbugs’ and especially those resistant to antibiotics.

Although the EU's activities in this field have led to some progress, for example, in veterinary and food related issues, there is little evidence of any decrease in the impact of antimicrobial resistance.

The fact that around 33 000 people die of infections caused by drug-resistant bacteria in the EU every year is a cause for concern. In financial terms this also involves a cost of some EUR 1.5 billion in additional healthcare expenditure and productivity losses.

The EU budget is a major source of funding for antimicrobial resistance research.

Market failures that discourage private research into tackling antimicrobial resistance have yet to be properly remedied through concrete EU initiatives.

Given that antimicrobial resistance poses a serious threat to health, development and food security worldwide, how is the Commission planning to boost research into antimicrobial resistance throughout the EU?

Last updated: 3 February 2020Legal notice - Privacy policy